Investors

News & Releases

April 8th, 2021

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Potential to Treat Parkinson’s and Other Neurodegenerative DiseasesVICTORIA, BRITISH COLUMBIA April 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader…

March 25th, 2021

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern

• Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action • Binds to all tested variants of concern, likely because it targets a site other than…

March 17th, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year

• Immunoprecise and Genmab enter into a technology partnership targeting infectious disease • Immunoprecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation • Commenced trading on Nasdaq…

March 16th, 2021

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination TherapyVICTORIA, BRITISH COLOMBIA March 16, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”…